Hemispherx Biopharma (HEB) Reports Q1 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hemispherx Biopharma's (HEB) Orphan Medicinal Product Application for Ampligen Approved by EC
May 11, 2015 8:33 AM EDTHemispherx Biopharma (NYSE: HEB) announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission [EU/3/15/1480-EMA/OD/310/14] approving its Orphan Medicinal Product Application for Ampligen®, an experimental therapeutic, to treat Ebola Virus Disease (EVD). Thomas K. Equels, Executive Vice Chairman, states, "European Medicines Agency designation of Ampligen®/rintatolimod as an orphan drug is an important achievement in our path seeking commercial approval of Ampligen® as a prophylactic and early onset therapeutic for Ebola and other lethal viral diseases."... More
